TY - JOUR T1 - Screening of hepatitis and HIV infections in an alcohol and drug addiction treatment center TT - Alkol ve uyuşturucu madde bağımlıları tedavi merkezinde hepatit ve HIV enfeksiyonlarının taranması AU - Dagli, Ozgur PY - 2020 DA - January Y2 - 2019 DO - 10.31362/patd.644886 JF - Pamukkale Medical Journal JO - Pam Tıp Derg PB - Pamukkale University WT - DergiPark SN - 1308-0865 SP - 177 EP - 186 VL - 13 IS - 1 LA - en AB - Purpose: Positivity of HBsAg, anti HCV, andanti HIV can expected to be higher in patients treated in an Alcohol and Drug Addiction Treatment Center (ADATC)as they have many risk factors. In this study, screening of these serologicmarkers in hospitalised patients was aimed.Materialand Methods: Atotal of 434 patients with a history of alcohol, injecting or noninjecting drugabuse who received treatment in Bursa ADATC unit in 2016 were included in thestudy. Patient’s files were retrospectively screened for HBsAg, anti HCV, anti HIV positivity and demographic features.Results: Of the 434 patients included in thestudy with a mean age of 31.95 ± 11.42years. HbsAg and anti HCV positivity were 2.8%, and 1.4% respectively. None ofthe patients had HIV positivity. 59.2% of the patients had a family history ofdrug use.Conclusion:It was found that the prevalence ofhepatitis B or hepatitis C was higher in the patients who had begun drug use in9-12 age range, or in the patients who were homeless, who had no social supportand living alone. Screening of these infections in ADATC is important forpublic health which will provide prevention and treatment of these diseases. KW - Addiction KW - HBV KW - HCV KW - HIV N2 - Amaç: HBsAg, anti HCV ve anti HIVpozitifliğinin, bir Alkol ve Uyuşturucu Madde Bağımlıları Tedavi Merkezi'nde(AMATEM) tedavi edilen hastalarda, bir çok risk faktörüne sahip olmalarınedeniyle daha yüksek olması beklenebilir. Bu çalışmada, hastanede yatanhastalarda bu serolojik belirteçlerin taranması amaçlandı.Gereç ve Yöntem: Çalışmaya 2016 yılında Bursa AMATEMünitesinde yatarak tedavi gören alkol, intravenöz veya intravenöz olmayan madde bağımlılığı öyküsü olan toplam 434hasta dahil edildi. Hasta dosyaları geriye dönük olarak HBsAg, anti HCV, antiHIV pozitifliği ve demografik özellikler açısından tarandıBulgular: Çalışmaya alınan 434 hastanınortalama yaşları 31,95 ± 11,42 yıl, HbsAg ve anti HCV pozitifliği ise sırasıyla% 2,8 ve % 1,4 idi. Hastaların hiçbirinde HIV pozitifliği saptanmadı.Hastaların% 59,2'sinde ailede uyuşturucu kullanımı öyküsü vardı.Sonuç: Hepatit B veya hepatit Cprevalansının, 9-12 yaş aralığında madde kullanmaya başlayanlarda veya evsiz, sosyal destek almayan ve yalnızyaşayan hastalarda yüksek olduğu bulundu. Bu enfeksiyonların AMATEM’detaranması halk sağlığı açısından önemli olup bu hastalıkların önlenmesini vetedavisini sağlayacaktır. CR - 1. Basu D, Sharma AK, Gupta S, Nebhinani N, Kumar V. Hepatitis C virus (HCV) infection & risk factors for HCV positivity in injecting & non-injecting drug users attending a de-addiction centre in northern India. The Indian journal of medical research 2015;142:311. https://doi.org/10.4103/0971-5916.166596 CR - 2. Mutlu EA, Altıntoprak AE and Tokuçoğlu L. Seroprevalence of hepatitits B, hepatitits C, HIV and syphilis infections among non-injecting drug users. Anadolu Psikiyatri Derg 2015;16:65-68. https://doi.org/10.5455/apd.152522 CR - 3. Ruiseñor-Escudero H, Wirtz AL, Berry M, et al. Risky behavior and correlates of HIV and Hepatitis C Virus infection among people who inject drugs in three cities in Afghanistan. Drug & Alcohol Dependence 2014; 143: 127-133. https://doi.org/10.1016/j.drugalcdep.2014.07.022 CR - 4. Ott J, Stevens G, Groeger J, Wiersma S. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30:2212-2219. https://doi.org/10.1016/j.vaccine.2011.12.116 CR - 5. Gurol E, Saban C, Oral O, Cigdem A, Armagan A. Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. European journal of epidemiology 2006; 21:299-305. https://doi.org/10.1007/s10654-006-0001-2 CR - 6. Evren C, Bilici R, Üçbilek E, İnan D. Türkiye'de damar içi madde kullanan kişilerde hepatit C enfeksiyonunu önlemeye yönelik eylem çağrısı. Dusunen Adam 2017;30:271-277. https://doi.org/10.5350/dajpn20173004001 CR - 7. Alaei A, Alaei K, Waye K, et al. Hepatitis C infection and other drug‐related harms among inpatients who injected drugs in Turkey. Journal of viral hepatitis 2017;24:496-505. https://doi.org/10.1111/jvh.12662 CR - 8. Mutlu E, Alaei A, Tracy M, Waye K, Cetin MK, Alaei K. Correlates of injection drug use among individuals admitted to public and private drug treatment facilities in Turkey. Drug & Alcohol Dependence 2016;164:71-81. https://doi.org/10.1016/j.drugalcdep.2016.04.032 CR - 9. Fuster D, Sanvisens A, Bolao F, Rivas I, Tor J, Muga R. Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. World journal of hepatology 2016;8:1295. https://doi.org/10.4254/wjh.v8.i31.1295 CR - 10. Singal AK, Anand BS. Mechanisms of synergy between alcohol and hepatitis C virus. Journal of clinical gastroenterology 2007;41:761-772. https://doi.org/10.1097/mcg.0b013e3180381584 CR - 11. Nolan S, Walley AY, Heeren TC, et al. HIV-infected individuals who use alcohol and other drugs and virologic suppression. AIDS care 2017;29:1129-1136. https://doi.org/10.1080/09540121.2017.1327646 CR - 12. Mirsal H, Kalyoncu A, Pektas O, Tan D, Beyazyurek M. The prevalance of hepatitis B, C and HIV seropositivity among iv heroin users. J Depend 2003; 4:10-14. CR - 13. Cicek IE, Cicek E, Kayhan F, et al. The roles of BDNF, S100B, and oxidative stress in interferon-induced depression and the effect of antidepressant treatment in patients with chronic viral hepatitis: a prospective study. J Psychosom Res 2014;76:227-232. https://doi.org/10.1016/j.jpsychores.2014.01.003 CR - 14. Tang LS, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. Jama 2018; 319: 1802-1813. https://doi.org/10.1001/jama.2018.3795 CR - 15. Sterling RK, Dharel N. Treatment of hepatitis C, then, now and tomorrow. BMJ Evidence-Based Medicine 2015;20:23-23. https://doi.org/10.1136/ebmed-2014-110103 CR - 16. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. Jama 2014;312:631-640. https://doi.org/10.1001/jama.2014.7085 CR - 17. Gu W-G. Newly approved integrase inhibitors for clinical treatment of AIDS. Biomedicine & Pharmacotherapy 2014; 68:917-921. https://doi.org/10.1016/j.biopha.2014.09.013 CR - 18. Aktaş EÖ, Koçak A, Şenol E, ve ark. Ege Bölgesinde ele geçirilen narkotik maddeler ve madde bağımlılarının incelenmesi. Turkiye Klinikleri Journal of Forensic Medicine and Forensic Sciences 2006;3:13-24. CR - 19. Avşar G, Koç F, Aslan G. Madde bağımlısı hastalarda sosyal destek ve benlik saygısı ACU Sağlık Bil Derg 2016(1):44-49. CR - 20. Yüncü Z, Basay BK, Özbaran B, Aydin C, Tamar M. Madde kullanim bozuklugu olan ergenlerde HBV: Yayginlik, riskler, asilama/Hepatitis B virus among adolescents with substance use disorder: Prevalence, risks, vaccinization. Anadolu Psikiyatri Dergisi 2008;9:208. CR - 21. Yüncü Z, Saatçioğlu H, Aydın C, Özbaran B, Altıntoprak E, Köse S. Bir şehir efsanesi: madde kullanmaya başlama yaşı düşüyor mu. Literatür Sempozyum 2014;1 (4): 43.2014;50. CR - 22. Karakukcu C, Ciraci MZ, Kocer D, Erturk Zararsiz G, Reyhancan M , Altintop I. Regional drug abuse prevalence depending on laboratory based urine illicit drug screening results. Anadolu Psikiyatri Derg 2018;19:169-176. https://doi.org/10.5455/apd.264474 CR - 23. Tekin K. Gençlere yönelik güncel tehdit: bonzai Bağımlılığı. Turkiye Klinikleri Journal of Psychiatric Nursing-Special Topics 2015;1:1-5. CR - 24. Karaaziz M, Keskindağ B. Gençler arasındaki popüler psikoaktif madde; sentetik kannabinoid (bonzai): bir gözden geçirme. Klinik Psikiyatri Dergisi 2016;19:137-144. https://doi.org/10.5505/kpd.2016.03522 CR - 25. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clinical Microbiology and Infection 2015;21:1020-1026. https://doi.org/10.1016/j.cmi.2015.06.028 CR - 26. Stasi C, Silvestri C, Voller F, Cipriani F. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine. Journal of infection and public health 2016;9:389-395. https://doi.org/10.1016/j.jiph.2015.05.004 CR - 27. Lanini S, Easterbrook PJ, Zumla A, Ippolito G. Hepatitis C: global epidemiology and strategies for control. Clinical Microbiology and Infection 2016;22:833-838. https://doi.org/10.1016/j.cmi.2016.07.035 CR - 28. Gökengin D. Türkiye’de HIV infeksiyonu: hedefe ne kadar yakınız? Klimik Dergisi 2018;31:4-10. https://doi.org/10.5152/kd.2018.04 CR - 29. Kandemir Ö, Gültekin O. Kronik hepatit C enfeksiyonlu damar içi uyusturucu madde kullanicilarinda hepatit C virüs genotiplerinin dagilimi/distribution of hepatitis C virus genotypes in injection drug users with chronic hepatitis C. Türkiye Klinikleri. Tip Bilimleri Dergisi 2017;37:21. https://doi.org/10.5336/medsci.2016-54118 CR - 30. Duffell EF, Hedrich D, Mardh O, Mozalevskis A. Towards elimination of hepatitis B and C in european union and european economic area countries: monitoring the World Health Organization’s global health sector strategy core indicators and scaling up key interventions. Eurosurveillance 2017;22:30476 https://doi.org/10.2807/1560-7917.es.2017.22.9.30476 UR - https://doi.org/10.31362/patd.644886 L1 - https://dergipark.org.tr/en/download/article-file/938789 ER -